Dr. Ann MacLaren has over 20 years of experience in the biotechnology industry, with significant expertise in pharmacology, IND enabling safety evaluations, development of PK, PD and predictive biomarker strategies for early clinical development, and preparation of regulatory documents (pre-IND, IND and EOP1).  Her therapeutic modality experience has focused primarily on biologics and includes peptides, antibodies, bispecific antibodies, antibody peptide conjugates and antibody drug conjugates.  Most recently she has been focused on the development of an antibody drug conjugate and contributed and later led its development from the pre-IND setting through to the completion of a Phase 1 study. 

Prior to joining Kivu Bioscience, she was Vice President of R&D at Klondike BioPharma, Executive Director of Translational Development at Triphase Accelerator, Director of Biology at Convoy Therapeutics, Principal scientist at Pfizer (CovX Biotherapeutics Unit) and Senior Scientist at Biogen Idec Inc. Dr. MacLaren obtained her Ph.D. in Molecular Biology from the University of Edinburgh, followed by post-doctoral training at the Beatson Institute for Cancer Research and The Scripps Research Institute.